3SOF

GNBT is looking interesting here.  I will be watching to buy if it breakes above 2.27.  I'll wait for some vollume to kick in, but I love the rounding bottom set up.

Everything is evening out and the 50 MA is about to cross over the 200 MA.  If volume picks up and the two cross, any news will send this thing just that much higher. with the flu season in, there will be plenty of news.
Buying at 2.27 sounds like an excellent idea. 
Best of luck!

Update:
GNBT is still inside this consolidation pattern, the $2.25 level is still causing some trouble, and volume continues to decrease. We expect an upside breakout with volume at any moment, so we'll be waiting with the same plan:

Trading Plan:
Hold with a stop @ $1.95

Best regards,

Update:
GNBT continues to trade inside the consolidation triangle, with the $2.25 barrier stopping every advance... 
We are still confident that GNBT is reserving an upside breakout any time soon, but taking in consideration the ascending support standing near $2.12, we should upgrade out stop level at this time (no reason for having so much room with the current stop at $1.95), so the new stop will be $2.05.

Trading Plan:
Hold with a stop @ $2.05

Best regards,

...added at $2.13 today

Quote from: 422fwhp on November 24, 2006, 11:59:57 AM
...added at $2.13 today

  Low risk anyways...took out the $2.05 stops this a.m....I'll wait for the end of the day to evaluate.

GLTA...Jody

Quote from: 422fwhp on November 27, 2006, 10:44:52 AM

Quote from: 422fwhp on November 24, 2006, 11:59:57 AM
...added at $2.13 today

  Low risk anyways...took out the $2.05 stops this a.m....I'll wait for the end of the day to evaluate.

GLTA...Jody

There should be support at 2.00 both due to the 200 and 50 sma about to do a Golden Cross there and due to it being a psychological level.  Tough market today, made GNBT break its trend line, but I do plan to hold since i have a lower entry and can afford a bit of leeway.

3SOF sold GNBT @ $2.05 following our trading plan 

Generex Biotechnology Announces New Oral Insulin Clinical Data
Tuesday November 28, 9:45 am ET

Results Show Achievement of Improved Glucose Control in Patients With Type-1 Diabetes

TORONTO--(MARKET WIRE)--Nov 28, 2006 -- Generex Biotechnology Corporation (NASDAQ:GNBT - News), the leader in drug delivery for metabolic diseases through the inner lining of the mouth, today announced new clinical data from a trial of Generex Oral-lyn, the Company's proprietary oral insulin spray product.

ADVERTISEMENT
The study compared the effects of two forms of prandial (mealtime) insulin in patients with Type-1 diabetes mellitus maintained on basal isophane insulin (NPH): Generex Oral-lyn versus pre-prandial subcutaneous injections of regular bolus insulin.

NPH is an intermediate acting insulin that peaks between 6-8 hours and may last as long as 8-10 hours or more. It has in recent years been replaced in some parts of the world by glargine, a basal insulin analogue. Regular insulin is a bolus or mealtime insulin taken a half hour before eating to combat post-meal blood glucose surges. Generex Oral-lyn is regular bolus insulin delivered by spray into the mouth (using the Company's proprietary RapidMist(TM) device) and is designed to replace mealtime insulin injections. NPH is the only longer acting insulin used in many parts of the world. The pharmacokinetics of Generex Oral-lyn (duration 2 hours) make it complementary to NPH, both functionally and economically. Unlike "inhaled" insulin products, Generex Oral-lyn does not enter the lungs; rather, the insulin is absorbed by the inner lining of the mouth.

In this study, 11 subjects in the control group received twice daily injections of NPH and three pre-meal injections of regular insulin. 14 subjects in the treatment group received twice daily injections of NPH and three split-dose applications of Generex Oral-lyn (i.e. RapidMist puffs of Generex Oral-lyn before and after meals). The comparison phase, following a stabilization phase, lasted 99 days with fructosamine and glycated hemoglobin (HbA1c) determined, on average, every 14 days.

The study demonstrated that both Generex Oral-lyn and mealtime injections of regular insulin achieved near normalization of metabolic control parameters as reflected by continuous improvement in fructosamine and HbA1c concentrations. In fact, a straightforward comparison of HbA1c during the comparison phase showed a superior effect for Generex Oral-lyn. By providing a safe, simple, fast, flexible, familiar, and effective alternative to mealtime insulin injections, Generex Oral-lyn is designed to improve patient compliance which promotes metabolic stability which in turn delays the onset and reduces the severity of the complications associated with diabetes.

This study provides the format for the Company's pivotal late-stage, long-term trial of Generex Oral-lyn in 300 patients which will begin early in 2007.

http://biz.yahoo.com/iw/061128/0188687.html

gnbt had promising  trial results from a cancer vaccine. any ideas where this sends the pps short term? soxguy

Up .35 - 20% in premarket on positive news.

7:17AM Generex Biotech says clinical trial results from cancer vaccine show that vaccine is safe, well-tolerated (GNBT) 1.75 : Co announces the results of clinical studies on a novel cancer vaccine being developed by its wholly owned immunotherapeutics subsidiary, Antigen Express, will be presented at the Annual San Antonio Breast Cancer Symposium. Co says the trials have shown that the vaccine is safe, well-tolerated and produces a significant immune response in breast cancer patients. While the target of AE37 is the same as that of the marketed cancer drug Herceptin, co says the activity of AE37 relies on its ability to stimulate a patient's own immune system to recognize the cancer target rather than by interacting with the target directly. They say the advantage of this is that the immune system, once activated, is capable of detecting lower levels of the target protein than is Herceptin and that the anti-tumor activity lasts long after termination of AE37 treatment.

I got stopped out on this at 1.95 shortly after 3SOF sold, but have been in no hurry to buy back.  Based on the chart right now, I just put in a limit order for the gap fill that could take place.

Quote from: tokyopua on December 14, 2006, 10:07:34 AM
I got stopped out on this at 1.95 shortly after 3SOF sold, but have been in no hurry to buy back.  Based on the chart right now, I just put in a limit order for the gap fill that could take place.

Took awhile, but I finally got a position on the gap fill just now.  Hopefully 1.80 now acts as support!

Generex Biotechnology Corporation engages in the research, development, and commercialization of drug delivery systems and technologies for metabolic and immunological diseases. It develops a proprietary platform technology for the delivery of drugs into the human body through the oral cavity. The company's primary product, Oral-lyn is an insulin spray formulation used for the treatment of Type-1 and Type-2 diabetes. It also develops Glucose RapidSpray that delivers glucose through a pump spray to the mouth, as well as morphine and fentanyl by oral formulation and injection for the treatment of moderate to severe breakthrough and postoperative pain. In addition, the company develops technology for the oral administration of molecule drugs, including proteins, peptides, monoclonal antibodies, hormones, and vaccines. It also engages in the research and development of technologies and immunomedicines for the treatment of malignant, infectious, autoimmune, and allergic diseases.

An understatement is their development toward creating synthetic vaccines; and their insulin spray formulations DO NOT require inhalation into the lungs, they are absorbed in the lining of the mouth.

Generix is at a technical turning point in my opinion, and they have released news on Friday stating they have filed for a $150 mln stock shelf offering. (not stock dilution) The stock shelf offering firewalls hostile take over bids in my opinion.  I expect volatility on Tuesday for all the usual reasons, share holder misunderstandings of shelf offerings, end of year tax loss selling, and the prerequisite greed and fear elements. Coupled with 49 million in cash, and debt of only 2 million, I see the company completing all phases of their product trials, and making investors at this juncture quite happy.  Please do your DD and tell me something I don't know if you DO. 

See the chart -- I may post other T/A charts later.

Let's try again with that image...